Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan

Euro Surveill. 2016 Oct 20;21(42):30377. doi: 10.2807/1560-7917.ES.2016.21.42.30377.

Abstract

The 2014/15 influenza season in Japan was characterised by predominant influenza A(H3N2) activity; 99% of influenza A viruses detected were A(H3N2). Subclade 3C.2a viruses were the major epidemic A(H3N2) viruses, and were genetically distinct from A/New York/39/2012(H3N2) of 2014/15 vaccine strain in Japan, which was classified as clade 3C.1. We assessed vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children aged 6 months to 15 years by test-negative case-control design based on influenza rapid diagnostic test. Between November 2014 and March 2015, a total of 3,752 children were enrolled: 1,633 tested positive for influenza A and 42 for influenza B, and 2,077 tested negative. Adjusted VE was 38% (95% confidence intervals (CI): 28 to 46) against influenza virus infection overall, 37% (95% CI: 27 to 45) against influenza A, and 47% (95% CI: -2 to 73) against influenza B. However, IIV was not statistically significantly effective against influenza A in infants aged 6 to 11 months or adolescents aged 13 to 15 years. VE in preventing hospitalisation for influenza A infection was 55% (95% CI: 42 to 64). Trivalent IIV that included A/New York/39/2012(H3N2) was effective against drifted influenza A(H3N2) virus, although vaccine mismatch resulted in low VE.

Keywords: Influenza; Influenza Virus; Laboratory surveillance; vaccine and immunization; vaccine effectiveness.

MeSH terms

  • Adolescent
  • Antigens, Viral / immunology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Influenza A Virus, H3N2 Subtype / classification
  • Influenza A Virus, H3N2 Subtype / genetics
  • Influenza A Virus, H3N2 Subtype / immunology*
  • Influenza A Virus, H3N2 Subtype / isolation & purification*
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / immunology
  • Influenza, Human / epidemiology
  • Influenza, Human / genetics
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control*
  • Japan / epidemiology
  • Male
  • Population Surveillance
  • Respiratory Tract Infections / prevention & control
  • Respiratory Tract Infections / virology
  • Seasons
  • Treatment Outcome
  • Vaccination / statistics & numerical data
  • Vaccines, Inactivated*

Substances

  • Antigens, Viral
  • Influenza Vaccines
  • Vaccines, Inactivated